Wyvern
11007 Jasper Ave NW, Suite 466, Edmonton, AB, T5K 0K6, Canada
Overview
Wyvern was created to unlock the secrets of the electromagnetic spectrum by providing groundbreaking access to high-resolution and quality imagery. The hyperspectral sensors on our Dragonette satellites will capture data in many narrow spectral bands, allowing for the identification of unique chemical and physical properties of the Earth's surface. This makes Wyvern's hyperspectral imagery data an extremely valuable tool for a wide range of site monitoring, mapping and geospatial intelligence (GEOINT) use-case applications.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 5
Sector focus
- Aerospace
- Big Data
- Geospatial
Investment portfolio
- Apitope
Participated · Series B · Sep 2015
Apitope focuses on discovery and development of disease-modifying therapies for autoimmune and allergic diseases using a proprietary platform technology. Its pipeline includes candidates for multiple sclerosis, Graves’ disease, Factor VIII intolerance in Haemophilia A patients and uveitis. The company’s first product candidate is licensed to Merck Serono, and its lead candidate, ATX-F8-117, has received orphan designations in both Europe and the USA. Apitope intends to use the Series B proceeds to progress clinical development of its remaining portfolio. The company is led by CEO Dr Keith Martin and will relocate its UK headquarters to Wales. The financing supports advancement of its clinical programs toward regulatory milestones.